
Since the biology, pharmacology and zzso of pediatric cancer is so different from cancer in adults, it is impossible to extrapolate from adult cancer experience; however, conducting studies in children with cancer is ethically and clinically very zzso This is especially so in phase 1 trials, aimed at dose finding for new zzso where the chances to cure the child who failed standard therapy are marginal to zzso zzso the child may be exposed to risks and discomfort which may be unbalanced by potential zzso This situation, which is difficult for zzso adults, is much more complex when a parent gives proxy zzso This review addresses the ethical and clinical framework of such studies in the most vulnerable of zzso 

